New drug combo aims to fight stomach cancer

NCT ID NCT06841679

Recruiting now Disease control Sponsor: Beijing Biostar Pharmaceuticals Co., Ltd. Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study tests a new chemotherapy drug called utidelone, given as a capsule, together with standard chemotherapy for people with advanced stomach or gastroesophageal junction cancer that has not been treated before. The trial will enroll about 778 participants across multiple countries. Researchers want to see if the combination helps people live longer and shrinks tumors, while also checking for side effects.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: Utidelone capsule (a chemotherapy drug) combined with standard chemotherapy (capecitabine, oxaliplatin, or FOLFOX)
What this could lead to: If successful, this could provide a new first-line treatment option for advanced stomach cancer, potentially improving survival and tumor shrinkage.
What could go wrong: This is an early-to-mid stage trial (phase 2/3) and the drug combination may cause significant side effects. It may not prove more effective than current standard treatments.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for GASTRIC ADENOCARCINOMA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

gastric adenocarcinoma gastroesophageal adenocarcinoma gastroesophageal junction adenocarcinoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

GASTRIC OR GASTROESOPHAGEAL JUNCTION ADENOCARCINOMA

Contacts and locations

Locations

AnYang Tumor Hospital
RECRUITING

Anyang, China
Bioresearch Partner
NOT_YET_RECRUITING

Hialeah, Florida, 33013, United States
Henan Cancer Hospital
RECRUITING

Zhengzhou, China
Jinan Municipal Central Hospital
RECRUITING

Jinan, China
Liaoning Cancer Hospital
RECRUITING

Shenyang, China
Shandong First Medical University Affiliated Tumor Hospital
RECRUITING

Jinan, China
Shanxi Cancer Hospital
NOT_YET_RECRUITING

Taiyuan, China
Sun Yat-sen University Cancer Center
RECRUITING

Guangzhou, China
Tianjin Medical University Cancer Institute & Hospital
NOT_YET_RECRUITING

Tianjin, China
Union Hospital, Tongji Medical College, Huazhong University of Science and Technology
NOT_YET_RECRUITING

Wuhan, China

More trials for these conditions

Other studies related to the condition(s) this trial covers.